Toll-like Receptor 4 (TLR4) is a pivotal protein in innate immunity. Its role is to recognize bacterial presence by binding lipopolysaccharide (LPS): upon LPS binding, inflammation is triggered.1,2 Inflammation is our way to fight threats. While indispensable for survival, excessive inflammation can lead to sepsis or autoimmune diseases, while weak inflammation can lead to incorrect immunity functions.1,2 Our aim is to control the inflammatory response by modulating TLR4 activity: inhibiting it can lead to treatments for sepsis and autoimmune diseases; eliciting it can be useful for vaccine adjuvants and cancer immunotherapy. We achieve this goal using our proprietary and patented FP Compounds.3,4,5
Romerio, A., Shaik, M., Italia, A., Lami, F., Galimberti, M., Fumagalli, G., et al. (2026). Harnessing Immunity: Synthesis of New Modulators of Toll-like Receptor 4 (TLR4). In Book of Abstracts (pp.27-27).
Harnessing Immunity: Synthesis of New Modulators of Toll-like Receptor 4 (TLR4)
Romerio, A;Shaik, MM;Italia, A;Lami F;Peri, F
2026
Abstract
Toll-like Receptor 4 (TLR4) is a pivotal protein in innate immunity. Its role is to recognize bacterial presence by binding lipopolysaccharide (LPS): upon LPS binding, inflammation is triggered.1,2 Inflammation is our way to fight threats. While indispensable for survival, excessive inflammation can lead to sepsis or autoimmune diseases, while weak inflammation can lead to incorrect immunity functions.1,2 Our aim is to control the inflammatory response by modulating TLR4 activity: inhibiting it can lead to treatments for sepsis and autoimmune diseases; eliciting it can be useful for vaccine adjuvants and cancer immunotherapy. We achieve this goal using our proprietary and patented FP Compounds.3,4,5
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
